Form 4: Prelude Therapeutics Executive Jane Huang Reports Stock Transactions
SEC Form 4 Filing
Jane Huang, President and CMO of Prelude Therapeutics, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On October 4, 2024, Jane Huang, President and CMO of Prelude Therapeutics, reported transactions involving the company's common stock.
- Huang acquired 9,375 shares of common stock through the vesting of Restricted Stock Units (RSUs).
- The issuer withheld 3,349 shares to satisfy tax obligations related to the RSU vesting.
- Following these transactions, Huang directly owns 63,341 shares of Prelude Therapeutics common stock and 56,250 Restricted Stock Units.
- The RSUs were granted on May 2, 2022, and vest quarterly, subject to continued service.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.
Key Dates
| Date | Description |
|---|---|
| May 2, 2022 | Date the RSUs were granted to Jane Huang. |
| April 4, 2023 | Date when 1/4 of the total RSU shares vested. |
| October 4, 2024 | Date of the reported transactions: RSU vesting and tax withholding. |
| October 7, 2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.